Showing 2331-2340 of 18625 results for "".
Analyzing IL-31 and the Benefits of Blocking It
https://reachmd.com/programs/dermatology-hub-neuroimmune-network/analyzing-il-31-and-the-benefits-of-blocking-it/48777/James Q. Del Rosso, DO, FAOCD, discusses IL-31 and its involvement with itch, impairment of skin barrier function, and increased fibrosis of the skin.Real-World CDK4/6 Inhibitor Patterns in HR+/HER2– Metastatic Breast Cancer
https://reachmd.com/programs/project-oncology/real-world-cdk46-inhibitor-patterns-in-hrher2-metastatic-breast-cancer/36161/CDK4/6 inhibitors play a central role in the first-line treatment of hormone receptor-positive, HER2-negative (HR+/HER2–) metastatic breast cancer, but how do they perform outside of clinical trials? That’s what a recent real-world study aimed to find out, examining treatment patterns, tolerability,The Mechanism of Itch
https://reachmd.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37155/Alina Bridges, DO, Director of Dermatopathology & Associate Professor in the Department of Dermatology and Anatomic Pathology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, discusses the mechanism of itch and how that understanding should influence treating patients wiInvestigating Inebilizumab for Generalized Myasthenia Gravis: Results from MINT
https://reachmd.com/programs/neurofrontiers/investigating-inebilizumab-for-generalized-myasthenia-gravis-results-from-mint/35495/Recently published in The New England Journal of Medicine, the phase 3 Myasthenia Gravis Inebilizumab Trial (MINT) underscores the potential of inebilizumab as a therapeutic option for patients with generalized myasthenia gravis (gMG). This is based on the efficacy findings that inebilizumab signifiReviewing RSV in Immunocompromised Adults
https://reachmd.com/programs/deep-breaths-updates-chest/reviewing-rsv-in-immunocompromised-adults/15336/How common is RSV in immunocompromised adults? Dive in.The Impact of Individual Autonomic Domains in Parkinson’s Disease
https://reachmd.com/programs/neurofrontiers/the-impact-of-individual-autonomic-domains-in-parkinsons-disease/14235/Are patients with Parkinson’s disease who experience impairment of the autonomic nervous system at greater risk for aggressive disease progression?Iron Sequestration in Microbiota Biofilms in Treatment for IBD
https://reachmd.com/programs/Audioabstracts/iron-sequestration-in-microbiota-biofilms-in-treatment-for-ibd/10712/This integrative study provides deeper understanding of the interactivity between microbiota and anti-inflammatory drugs currently used to treat IBD.Behind-the-Scenes Look into Health Information Exchange
https://reachmd.com/programs/primary-care-today/behind-the-scenes-look-into-health-information-exchange/10493/An astounding electronic evolution is continuing to improve healthcare and the transfer of information. How will data transform your patients’ care?Top Non-Pharmacologic Interventions for Rheumatoid Arthritis
https://reachmd.com/programs/conference-coverage/top-non-pharmacologic-interventions-for-rheumatoid-arthritis/10303/When it comes to improving your rheumatoid arthritis patients’ symptoms, these non-pharmacologic interventions cannot be overlooked.FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Serious Asthma Outcomes Risk
https://reachmd.com/programs/FDA-Drug-Information-Updates/fda-review-adding-labas-ics-treatment-does-not-significantly-increase-serious-asthma-outcomes-risk/9950/The FDA found no significant increase in risk of serious asthma outcomes combining long-acting beta agonists (LABAs) and inhaled corticosteroids (ICS)